- Pluripotent stem cells
Cellartis cardiomyocytes are derived from human induced pluripotent stem cells and provide a promising physiologically relevant human model for preclinical safety evaluation and drug screening. They can be used on multiple high-throughput platforms to accurately predict cardiotoxic responses and to efficiently screen compounds.
View our protocols below:
Perform real-time kinetic assessment of Ca2+ flux and cardiac beating using Cellartis cardiomyocytes with this protocol for the FLIPR Tetra High-Throughput Cellular Screening System.
Cellartis cardiomyocytes on ACEA Biosciences’ xCELLigence RTCA CardioECR system for impedance and EFP recordings
Collect impedance and EFP recordings from Cellartis cardiomyocytes with the xCELLigence RTCA CardioECR system.
Accurately predict cardiotoxic responses and screen compound efficacy with this protocol using Cellartis cardiomyocytes and Maestro MEA technology.
Assess electrophysiological behavior using Cellartis cardiomyocytes with this protocol for automated patch clamp recordings on the Patchliner system.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.